phosphonoacetic acid has been researched along with Opportunistic Infections in 18 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 7.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 3.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | 3.68 | [Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| " Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)." | 1.28 | [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis]. ( Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 15 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Jacobson, MA | 5 |
| Molina, JM | 1 |
| David, F | 1 |
| Scieux, C | 1 |
| Schnell, L | 1 |
| Gerrier, F | 1 |
| Kateb, M | 1 |
| Morinet, F | 1 |
| Modai, J | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Palestine, AG | 2 |
| Polis, MA | 1 |
| De Smet, MD | 1 |
| Baird, BF | 1 |
| Falloon, J | 1 |
| Kovacs, JA | 1 |
| Davey, RT | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Pinching, AJ | 1 |
| Lowenstein, W | 1 |
| Fadlallah, JP | 1 |
| Roudière, L | 1 |
| Deneux, C | 1 |
| Haas, C | 1 |
| Durand, H | 1 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Gümbel, H | 1 |
| Ohrloff, C | 1 |
| Schalnus, R | 1 |
| Helm, EB | 1 |
| Söderlund, C | 1 |
| Bratt, G | 1 |
| Grützmeier, S | 1 |
| Rieger, A | 1 |
| Sandström, E | 1 |
| Sjunnesson, M | 1 |
| Gambertoglio, JG | 1 |
| Aweeka, FT | 1 |
| Causey, DM | 1 |
| Portale, AA | 1 |
| Bratzke, B | 1 |
| Orfanos, CE | 1 |
| Stavermann, T | 1 |
| Ehlers, G | 1 |
| O'Donnell, JJ | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Mills, J | 1 |
| Bloom, JN | 1 |
| Richman, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
7 reviews available for phosphonoacetic acid and Opportunistic Infections
| Article | Year |
|---|---|
Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Comb | 1992 |
[Prophylactic treatments of opportunistic infections in acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Male; | 1992 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
3 trials available for phosphonoacetic acid and Opportunistic Infections
| Article | Year |
|---|---|
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
9 other studies available for phosphonoacetic acid and Opportunistic Infections
| Article | Year |
|---|---|
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec | 1992 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
[Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
[Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chorioretinitis; Cytomegalovirus Infections; D | 1991 |
[Cytomegalovirus ileocolitis in patients with HIV infection is a treatable cause of severe abdominal problems].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cecum; Crohn Disease; Cytomegalovirus I | 1991 |
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
Topics: Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Foscarnet; Herpes Simplex; Humans; Hypo | 1991 |
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship, | 1991 |